Sanofi announced this week that it will be slashing the list price of its most widely prescribed insulin, Lantus, by 78%, and its short-acting Apidra by 70%.
According to Sanofi, with the price discounts, no insured patient will pay more than $35 out of pocket for insulin. The new prices will go into effect January 1, 2024.
Last year, Sanofi launched its unbranded biologic for Lantus at 60% less than the branded list price. But, according to Olivier Bogillot, Sanofi's head of U.S. General Medicines, inherent structural challenges prevented the U.S. health system from taking advantage of the discount.
Now Sanofi is joining other drugmakers like Eli Lilly and Novo Nordisk who are providing hefty discounts to both their biosimilars and branded insulins.
